TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33710111
Drug: Non-prolonged prophylactic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prolonged prophylactic systemic antibiotics (non-PPSA) administered for 24 hours postoperatively
Study: 34622731
Drug: Oral D-methionine
Normalized name: D-Methionine
DrugBank: D-Methionine (DB02893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-methionine (D-met)
Study: 34960093
Drug: INV-MFGM (investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: INV-MFGM (investigational cow's milk-based IF/100 kcal: 1.9 g protein, 1.2 mg iron, 25 mg ARA and whey protein-lipid concentrate, 5 g/L (source of bMFGM))
Study: 34960093
Drug: Control (marketed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (marketed, routine cow's milk-based IF/100 kcal: 2.1 g protein, 1.8 mg iron, 34 mg ARA)
Study: 34001705
Drug: Control app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Control app allowing daily reporting of sexual behaviour and medication intake
Study: 32552074
Drug: Short tablet
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short tablet training (Control)
Study: 34118123
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of dexketoprofen
Study: 34118123
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of paracetamol
Study: 33816430
Drug: Seeking health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seeking health advice or treatment
Study: 35123290
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy (DBT) for 12 weeks
Study: 33617699
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 10 weekly sessions
Study: 36232205
Drug: Standard message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard message on oral rehydration solution
Study: 34636752
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (1.5 mg/kg bolus of 1% lidocaine after anesthesia induction followed by a continuous infusion of 2 mg/kg/h up to 1 h after surgery)
Study: 34032710
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy plus adjuvant gemcitabine plus cisplatin
Study: 34032710
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy plus adjuvant 5-fluorouracil plus cisplatin
Study: 34130883
Drug: Moderna vaccine
Normalized name: Moderna COVID-19 Vaccine
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderna vaccine (1 dose)
Study: 37072577
Drug: Glimepiride 4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 4 mg/day
Study: 34398956
Drug: LPV/r 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 400 mg/100 mg twice daily + RBT 150 mg/day (Arm A)
Study: 34398956
Drug: LPV/r 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 800 mg/200 mg twice daily + RIF 600 mg/day (Arm B)
Study: 34398956
Drug: LPV/r 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 400 mg/100 mg twice daily + RAL 400 mg twice daily + RBT 150 mg/day (Arm C)
Study: 32423396
Drug: Journal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Journal therapy counseling (3 in-person sessions and 3 telephone sessions)
Study: 34773292
Drug: Thalidomide 25
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 25 mg/d
Study: 34773292
Drug: Thalidomide 50
Normalized name: thalidomide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 50 mg/d
Study: 32210157
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (reference group)
Study: 35976944
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (1000 μg MK‐7/day)
Study: 34735762
Drug: Subanesthetic IV
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic IV ketamine (0.3 mg/kg)
Study: 34735762
Drug: Caudal 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.125% bupivacaine (1 ml/kg)
Study: 34776421
Drug: Vibratory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibratory stimulation during 2-week task-practice therapy
Study: 34776421
Drug: No stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stimulation (control group) during 2-week task-practice therapy
Study: 37593838
Drug: Phentermine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine (37.5 mg)
Study: 35248274
Drug: Osteopathic Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Treatment (4 treatments over 8 weeks)
Study: 35248274
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (no osteopathic treatment)
Study: 35012538
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose group coaching (5 months)
Study: 35012538
Drug: Extended dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dose group coaching (5 months + 18 months one-on-one coaching)
Study: 35012538
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose group coaching with unstructured engagement of scientific advisors
Study: 35012538
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose group coaching with structured engagement of scientific advisors
Study: 34402784
Drug: Solriamfetol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (150 mg or 300 mg)
Study: 34402784
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg or 400 mg)
Study: 33290635
Drug: Conventional symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional symptomatic treatment (Miconaz oral gel, BBC oral spray)
Study: 33290635
Drug: 3% chamomile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% chamomile topical oral gel
Study: 33290635
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + 3% chamomile topical oral gel
Study: 36351174
Drug: No sodium
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No sodium bicarbonate infusion (control group)
Study: 34073203
Drug: Hybrid model
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid model based on 3D structure of peptides; specific dosage and duration not mentioned.
Study: 34073203
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro experiments with five randomly selected novel ACPs; specific dosage and duration not mentioned.
Study: 32156842
Drug: Nano-curcumin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (120 mg) for 12 weeks
Study: 35972211
Drug: OCS (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCS (Oral Corticosteroids)
Study: 34332788
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/Ω-3 fatty acids 4 g (UI-018)
Study: 34332788
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg + placebo (control)
Study: 33196567
Drug: Sequential procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential procedure (scleral-fixated IOL implantation followed by DSAEK)
Study: 32861614
Drug: Interprofessional intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interprofessional intervention focusing on neuroleptics and potentially inadequate medications
Study: 34755262
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (127 patients)
Study: 34755262
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (13 patients)
Study: 32068426
Drug: SMT (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT (standard manualized treatments)
Study: 33606009
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single 1-g dose)
Study: 33457425
Drug: Metformin (≤1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (≤1000 mg/d) added to insulin for 24 weeks
Study: 33402601
Drug: Drip intravenous
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip intravenous administration of endostar (DE)
Study: 33402601
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous administration of endostar (CE)
Study: 34347883
Drug: Crenezumab (600–7,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenezumab (600–7,200 mg)
Study: 34347883
Drug: Placebo (4–40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4–40 mL)
Study: 34347883
Drug: Crenezumab (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenezumab (high-dose, high-concentration, high-volume)
Study: 35978329
Drug: BI 764524
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764524 (0.5, 1.0, or 2.5 mg) in the SRD part
Study: 35978329
Drug: BI 764524
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764524 (maximum tolerated dose) in the MD part
Study: 33441760
Drug: Inland participants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inland participants (median UIC 188.5 μg/L)
Study: 33441760
Drug: Coastal participants
Normalized name: Coastal Water-hyssop Whole
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coastal participants (median UIC 128.5 μg/L)
Study: 35015777
Drug: Ad26.ZEBOV (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV (5 × 10^10 viral particles) and MVA-BN-Filo (1 × 10^8 infectious units) administered 28 or 56 days apart
Study: 33252337
Drug: CT-guided injection
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided injection with botulinum toxin
Study: 33252337
Drug: CT-guided injection
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided injection without botulinum toxin (Control)
Study: 35138714
Drug: Psilocybin in
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin in combination with psychotherapy
Study: 35138714
Drug: Escitalopram in
Normalized name: Product containing escitalopram in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram in combination with psychotherapy
Study: 35483093
Drug: Adaptive COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive COVID-19 Treatment Trial
Study: 32069516
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (fasting condition)
Study: 32069516
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (high-calorie, high-fat meal 1 hour postdose)
Study: 32069516
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (high-calorie, high-fat meal 2 hours postdose)
Study: 36228485
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day pyridoxine
Study: 33296464
Drug: Probiotics (Lactiplantibacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2) - total daily dose of 109 CFU for 12 weeks
Study: 32606658
Drug: Commercial etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial etoricoxib tablets
Study: 33280934
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality sessions for 15 min twice a week for 6 weeks
Study: 32505378
Drug: Dexmedetomidine [1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine [1.0 μg.kg‐1 body weight] and morphine [0.48 mg.kg‐1 body weight] (COM Group)
Study: 32505378
Drug: Morphine [0.48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine [0.48 mg.kg‐1] (MOR Group)
Study: 32505378
Drug: Dexmedetomidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine and morphine (COM Group)
Study: 32505378
Drug: Morphine (MOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (MOR Group)
Study: 33756250
Drug: BDC supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDC supplementation (150 mg/kg)
Study: 32620917
Drug: dMMR CRCs
Normalized name: PILOCARPINE 11MG/UNT OPH,CRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: dMMR CRCs bearing receptor tyrosine kinase fusion
Study: 36332823
Drug: Analog insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analog insulin
Study: 36174744
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous hydroxocobalamin (IV-HOC), 5-gram dose
Study: 35175317
Drug: Sacubitril/valsartan (194/206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (194/206 mg)
Study: 32657457
Drug: Glycopyrrolate up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate up to 4.5 mg/d
Study: 35708706
Drug: Port Delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Port Delivery System (PDS) with ranibizumab, 100 mg/mL, fixed refill exchanges every 24 weeks
Study: 35708706
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injections, 0.5 mg, every 4 weeks
Study: 35708706
Drug: Concurrent fellow-eye
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent fellow-eye injections
Study: 35734974
Drug: Hydrogen/oxygen inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen/oxygen inhalation for 13 weeks
Study: 35734974
Drug: Hydrogen/oxygen inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen/oxygen inhalation
Study: 35734974
Drug: Hydrogen treatment
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen treatment
Study: 34081385
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose to induce PBH
Study: 35437929
Drug: Sacubitril/valsartan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (200 mg/day)
Study: 32910197
Drug: Collagen/cell group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen/cell group (hUC-MSC-laden collagen hydrogel intramyocardial injection)
Study: 33527576
Drug: L-menthol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol (160 mg) and Placebo
Study: 35561721
Drug: Human intramuscular
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human intramuscular antitoxin
Study: 35561721
Drug: Equine intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine intramuscular antitoxin
Study: 33358790
Drug: High rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High rate of milk replacer (HMR treatments); n = 12 calves
Study: 36083793
Drug: Allogeneic cardiosphere-derived
Normalized name: Allogeneic Cardiosphere-Derived Cells
DrugBank: Allogeneic Cardiosphere-Derived Cells (DB15744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic cardiosphere-derived cell (CDC) therapy (20 × 10^6 CDCs)
Study: 36083793
Drug: Allogeneic cardiosphere-derived
Normalized name: Allogeneic Cardiosphere-Derived Cells
DrugBank: Allogeneic Cardiosphere-Derived Cells (DB15744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic cardiosphere-derived cell (CDC) therapy with cyclosporine (2.5 mg/kg iv and 100 mg/day po)
Study: 33781617
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health worker-led multicomponent intervention (health education, monthly telephone follow-ups, navigation assistance)
Study: 35779560
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once daily if <100 kg, 40 mg twice daily if ≥100 kg) for 21 days
Study: 33121228
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) infusion (8 µg/min)
Study: 33121228
Drug: Phenylephrine (PE)
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine (PE) infusion (100 µg/min)
Study: 32620262
Drug: High-dose TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TXA (50 mg kg−1 followed by 5 mg kg−1 h−1)
Study: 32620262
Drug: Low-dose TXA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TXA (10 mg kg−1 followed by 5 mg kg−1 h−1)
Study: 36494329
Drug: SOM3355 (bevantolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOM3355 (bevantolol hydrochloride) 200 mg twice daily
Study: 32199156
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of 0.45 g/kg
Study: 32358349
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with conventional therapy
Study: 34989759
Drug: Flower essence
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flower essence therapy (4 drops, 4 times a day for 60 days)
Study: 34849651
Drug: Standard ATT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ATT plus daily 1000 mg metformin (METRIF)
Study: 32979939
Drug: High-dose varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose varenicline (1 mg twice daily; 0.5 mg twice daily if bodyweight ≤55 kg)
Study: 32979939
Drug: Low-dose varenicline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose varenicline (0.5 mg twice daily; 0.5 mg once daily if bodyweight ≤55 kg)
Study: 35017115
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of anal HSIL
Study: 32763541
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus enhanced medication management (EMM)
Study: 32763541
Drug: PE plus
Normalized name: Acetaminophen/Phenylephrine Hydrochloride 500 MG-5 MG Oral Tablet [ORANYL PE PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE plus sertraline hydrochloride
Study: 34190422
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) at doses of 600 or 1000 mg per day for 12 weeks
Study: 34964262
Drug: Metformin during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin during pregnancy
Study: 34964262
Drug: Post partum
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post partum metformin concentration
Study: 34060169
Drug: Health literacy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health literacy education (four weekly training sessions)
Study: 34508365
Drug: Treatment reminders
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment reminders (outpatient appointment reminders a day before appointment and medication reminders on a weekly basis)
Study: 34508365
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without reminders
Study: 33929052
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (LiST) applied once weekly for 6 weeks
Study: 33929052
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (LiST) applied twice weekly for 3 weeks
Study: 33929052
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between once weekly and twice weekly LiST
Study: 35300814
Drug: Pelacarsen (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelacarsen (20-80 mg cumulative monthly doses)
Study: 34066319
Drug: Eight-session multicomponent
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight-session multicomponent intervention program based on group psychological therapy and adventure activities
Study: 35175414
Drug: Intravenous scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous scopolamine before stapling
Study: 35230177
Drug: PartyWise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PartyWise intervention (telephone screening, brief counseling, web-based resources, and up to 8 weekly text messages)
Study: 35705264
Drug: Bilateral posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral posterior quadratus lumborum block (QLB) with 20 mL of 0.375% ropivacaine on each side (150 mg total)
Study: 35705264
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.4 mg morphine sulfate)
Study: 35337143
Drug: Chisan®/ADAPT‐232 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chisan®/ADAPT‐232 (a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra) supplementation for two weeks
Study: 35337143
Drug: Chisan® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chisan® treatment
Study: 35181380
Drug: Recommendation agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendation agents
Study: 32441643
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) administered subcutaneously at 162 mg every 1 or 2 weeks in the GiACTA trial.
Study: 32441643
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) administered via standard IV dose (8 mg/kg/month) or subcutaneously (162 mg/week) in clinical practice.
Study: 35956412
Drug: Study formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study formulation (A)